Nuvectra?

LOL! You are joking, right? They only have 35 mil left in the bank....about a year. 5.5 million in sales is terrible even if they say 180ish growth from last year. 1/4 of Nuvectra's sales are not from Stim and they are operating from a loss more than double their sales. You do the math.

Lets agree to disagree-touch base with me after NANS 2018
 






They have 50 reps and did ~5million last qtr. after 2 yrs on the market. Not good. Mgmt team has decent reputation but the product hasn't turned enough heads. No clinical data, not High frequency = price driven sale.
Biggest warning sign is they have already begun working with US distributors. There are many good reasons why all the SCS players avoided that. Nuvectra is desperate though.

Their existence depends on performance in the urinary incontinence market. Hard to see them being profitable anytime soon, and at their low revenue footprint they are definitely in trouble.
 












I listened to earnings call also. The take away for me was 50 reps and only $5.5M for the quarter. Ok, that IS NOT an enviable revenue line for a company that has been commercial since early '16. In fact it's terrible. It was insulting to those investors on the call to hear that the number of "non-competes" is limiting their growth. It was essentially saying no one will buy the product unless there is a solid relationship. Not where you want to be if you're banking on that strategy. Also caught the one question that seemed to catch Mr D. off guard. "It appears that there are a small number of reps driving all the revenue". Bingo! Not much depth, just a few good users generating the bulk of cases.
 












Just give Burst some time to expose its ugly failure head. It will or maybe patients will like the nausea and throwing up to keep their slim, chronic pain figure. Burst might be the new weight loss stimulator!

And I pray for you who gets your asses chewed out when your poor patient demands why the hell they can't get an MRI due to low or high impedance. That will slowly but surely be exposed in due time. Time to redesign that shitty Octrode designed in the early 2000's? Better start working on it soon!

Burst DATA will be exposed long before 2yr timeframe of implant. Just watch!
 






Burst is over rated and Nuvectra is being taken for granted. Watch us dominate the rest of them and show why this technology is a sleeper as it continues to grow. Insult our stretchy leads, mock our 18v battery, and slam our 12 contact leads. You will all be eating crow shortly and watching your customers bail on your garbage systems and pick up the Algovita Dream!!
 






Burst is over rated and Nuvectra is being taken for granted. Watch us dominate the rest of them and show why this technology is a sleeper as it continues to grow. Insult our stretchy leads, mock our 18v battery, and slam our 12 contact leads. You will all be eating crow shortly and watching your customers bail on your garbage systems and pick up the Algovita Dream!!

Being taken for granted because any MD with a brain knows there is nothing different about the nuvectra waveform. Nevro's IP blocks the other companies from getting the superior outcomes associated with HF10. The fact that Nuvectra was brought to market with a 510k and not a PMA demonstrates very clearly that its the same thing Boston, SJM traditional, and Medtronic. PMA generate uniqeness. Little widgets mean nothing. Which is why your system is the lowest price.
 






Being taken for granted because any MD with a brain knows there is nothing different about the nuvectra waveform. Nevro's IP blocks the other companies from getting the superior outcomes associated with HF10. The fact that Nuvectra was brought to market with a 510k and not a PMA demonstrates very clearly that its the same thing Boston, SJM traditional, and Medtronic. PMA generate uniqeness. Little widgets mean nothing. Which is why your system is the lowest price.


Considering Boston's IPG isn't the same as STM traditional- you know a lot
 






the waveforms are not fundamentally different, which is why Boston was able to 510k off the technology preceeding it. SJM did the same thing off the MDT technology. As did Nuvectra.
 






the waveforms are not fundamentally different, which is why Boston was able to 510k off the technology preceeding it. SJM did the same thing off the MDT technology. As did Nuvectra.

Nuvectra is not very impressive. Not a slam, just not much new in its offering. Am I missing something? I've used Boston for about five years and hoping they figure out the HF thing without a lot of us having to switch to Nevro if they don't
 






Nuvectra is not very impressive. Not a slam, just not much new in its offering. Am I missing something? I've used Boston for about five years and hoping they figure out the HF thing without a lot of us having to switch to Nevro if they don't

using Boston but want HF? Are you a nursing assistant or an idiot.
 
























How did the quarter go for Nuvectra? Increasing traction? Tough sledding?

We are promoting a strong growth curve that with the guidance of SD and his experienced management team, will put us in a respectable place among other old and dated neuromodulation technologies. This is a difficult market to break into with so many other companies, but leadership is the difference maker and we have the best guiding our direction to the top
 






We are promoting a strong growth curve that with the guidance of SD and his experienced management team, will put us in a respectable place among other old and dated neuromodulation technologies. This is a difficult market to break into with so many other companies, but leadership is the difference maker and we have the best guiding our direction to the top

No chance Nucraptra stays alive. The three big companies have better technology and can handle the peaks and valleys in revenue better. Nucraptra's leads are falling apart inside of patients too.